|
|
polysorbitol-co-PEI polymer |
|
Vaxjo ID |
240 |
|
Vaccine Adjuvant Name |
polysorbitol-co-PEI polymer |
|
Adjuvant VO ID |
VO_0005727
|
|
Description |
A cationic polymer forming self-assembled nanocomplexes with nucleic acids (e.g., poly(I:C)); enhances antigen delivery and immune activation when used as an adjuvant |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Structure |
A polymer backbone combining sorbitol and branched PEI; forms nanoparticles when complexed with poly(I:C) |
|
Preparation |
Prepared by mixing PSPEI with poly(I:C) to form PSPEI-PIC nanocomplexes before injection |
|
Dosage |
Mice received 2.5 mg PSPEI + 50 µg poly(I:C) per injection, with or without dendritic cells and/or PD-L1 antibody (200 µg) |
|
Function |
By binding to different surface proteins, this nanocomplex enhances the intracellular delivery of cargos and induces potent anticancer immune responses against melanoma cells. |
|
Safety |
Well-tolerated in mice; promotes antitumor immunity without reported systemic toxicity; no increase in immunosuppressive cell populations like Tregs or MDSCs |
| References |
Vo et al., 2021: Vo MC, Ahn SY, Chu TH, Uthaman S, Pillarisetti S, Uong TNT, Lakshmi TJ, Kim M, Song GY, Jung SH, Yang DH, Ahn JS, Kim HJ, Park IK, Lee JJ. A combination of immunoadjuvant nanocomplexes and dendritic cell vaccines in the presence of immune checkpoint blockade for effective cancer immunotherapy. Cellular & molecular immunology. 2021; 18(6); 1599-1601. [PubMed: 33782574].
|
|
